Alcohol-Associated Hepatitis | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

Naltrexone is an approved drug for management of alcohol use disorder (AUD), but data in
patients with liver disease (LD) are limited. We aimed to evaluate the safety of naltrexone in …

Medications for alcohol use disorder promote abstinence in a... : Hepatology Medications for
alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a …

Objectives Management of alcohol use disorder (AUD) is rarely used in patients with liver
disease. We performed a systematic review to examine the impact of AUD management …

The COVID-19 pandemic is having substantial impacts on the health status of individuals
with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). AUD and ALD …

Liver transplantation (LT) teams must be adept at detecting, evaluating, and treating patients'
alcohol use, given its prominence among psychological and behavioral phenomena which …

Rising rates of alcohol use disorder (AUD) combined with increases in alcohol‐related liver
disease (ALD) and other liver disease have resulted in the need to develop alcohol …

Background/Aims Alcohol-related liver disease (ALD) is the medical manifestation of alcohol
use disorder, a prevalent psychiatric condition. Acute and chronic manifestations of ALD …

METHODS: Leveraging data from the Global Burden of Disease Study 2019, we analyzed
the prevalence, mortality, and disability-adjusted life years of alcohol-associated cirrhosis …